Delivered-To: john.podesta@gmail.com
Received: by 10.52.22.199 with SMTP id g7cs176020vdf;
        Thu, 8 Dec 2011 09:06:40 -0800 (PST)
Received: by 10.224.110.210 with SMTP id o18mr3802720qap.72.1323363999313;
        Thu, 08 Dec 2011 09:06:39 -0800 (PST)
Return-Path: <adesai@clintonfoundation.org>
Received: from ex07edge2.utopiasystems.net (ex07edge2.utopiasystems.net. [64.74.151.42])
        by mx.google.com with ESMTPS id hp8si4777012qab.70.2011.12.08.09.06.38
        (version=TLSv1/SSLv3 cipher=OTHER);
        Thu, 08 Dec 2011 09:06:39 -0800 (PST)
Received-SPF: pass (google.com: domain of adesai@clintonfoundation.org designates 64.74.151.42 as permitted sender) client-ip=64.74.151.42;
Authentication-Results: mx.google.com; spf=pass (google.com: domain of adesai@clintonfoundation.org designates 64.74.151.42 as permitted sender) smtp.mail=adesai@clintonfoundation.org
Received: from ex07cas12.utopiasystems.net (172.16.1.67) by
 ex07edge2.utopiasystems.net (172.16.1.71) with Microsoft SMTP Server (TLS) id
 8.3.213.0; Thu, 8 Dec 2011 12:06:33 -0500
Received: from CLINTON07.utopiasystems.net ([172.16.1.88]) by
 ex07cas12.utopiasystems.net ([172.16.1.67]) with mapi; Thu, 8 Dec 2011
 12:06:32 -0500
From: Amitabh Desai <adesai@clintonfoundation.org>
To: Hannah Richert - PC <hannah@presidentclinton.com>
CC: Bruce Lindsey <blindsey@clintonfoundation.org>, 
 Laura Graham <lgraham@clintonfoundation.org>, 
 Doug Band - PC <doug@presidentclinton.com>, 
 Justin Cooper - PC <justin@presidentclinton.com>, 
 =?us-ascii?Q?John_Podesta=0D=0A_=28john.podesta@gmail.com=29?= <john.podesta@gmail.com>, 
 "barilurie@gmail.com" <barilurie@gmail.com>
Date: Thu, 8 Dec 2011 12:06:16 -0500
Subject: for WJC: FW: Pharma Agreements
Thread-Topic: for WJC: FW: Pharma Agreements
Thread-Index: Acy1weRbBF8gPCfaQ8ac6pp0tcO7bwAANKsgAAAcYIAAAH2E4AAABs/wAACHNoAAAQzYUA==
Message-ID: <D00800C9D48A754DA64285EA077375750127C53AB1@CLINTON07.utopiasystems.net>
Accept-Language: en-US
Content-Language: en-US
X-MS-Has-Attach:
X-MS-TNEF-Correlator:
acceptlanguage: en-US
Content-Type: multipart/alternative;
	boundary="_000_D00800C9D48A754DA64285EA077375750127C53AB1CLINTON07utop_"
MIME-Version: 1.0
Return-Path: adesai@clintonfoundation.org

--_000_D00800C9D48A754DA64285EA077375750127C53AB1CLINTON07utop_
Content-Type: text/plain; charset="us-ascii"

Below is more information for the President, regarding domestic AIDS, from Ira:

From: Ira Magaziner
Sent: Thursday, December 08, 2011 11:46 AM
To: Amitabh Desai
Subject: FW: Pharma Agreements


Ami:

Following is a list of agreements we have forged with US and European pharmaceutical companies and selected negotiations we are having with them that are in advanced stages.


1.       An agreement with Pfizer on rifabutin to make it more widely available at a low price.


2.       An agreement with J&J on rilpivirine which has led to significant revisions in their overall access and licensing approach which will dramatically lower prices.


3.       An agreement with ViiV which is related to developing a new pediatric product and is also leading to a revisions in their access policy.


4.       Several agreements for price reductions on LPV/r with Abbott in the context of the UNITAID program


5.       An  agreement with BMS on ATV/r licensing


6.       An agreement with Merck to lower prices on a tiered basis for raltagravir


7.       An agreement with Novartis on licensing ACT malaria drugs



8.       Agreements with Gilead that led to their liberal licensing program



9.       An agreement with GSK to drastically lower the price of rotavirus vaccine.

In addition, we are currently in discussions with Merck and GSK about HPV vaccine, with GSK, Sanofi and J&J about polio vaccine and hexavalent vaccine formulations and GSK about malaria vaccine.

Thanks

Ira







From: Kate Condliffe
Sent: Thursday, December 08, 2011 11:02 AM
To: Ira Magaziner; David Ripin
Cc: Alan Staple
Subject: RE:

Copying Alan who will have the most recent list.

From: Ira Magaziner
Sent: Thursday, December 08, 2011 10:56 AM
To: David Ripin; Kate Condliffe
Subject:

I have been asked to supply a list of agreements we have done or are doing with Big Pharmaceutical companies (non generic). I know the vaccine ones. Could you please send me a list of others?

Thanks

Ira

--_000_D00800C9D48A754DA64285EA077375750127C53AB1CLINTON07utop_
Content-Type: text/html; charset="us-ascii"
Content-Transfer-Encoding: quoted-printable

<html xmlns:v=3D"urn:schemas-microsoft-com:vml" xmlns:o=3D"urn:schemas-micr=
osoft-com:office:office" xmlns:w=3D"urn:schemas-microsoft-com:office:word" =
xmlns:x=3D"urn:schemas-microsoft-com:office:excel" xmlns:p=3D"urn:schemas-m=
icrosoft-com:office:powerpoint" xmlns:a=3D"urn:schemas-microsoft-com:office=
:access" xmlns:dt=3D"uuid:C2F41010-65B3-11d1-A29F-00AA00C14882" xmlns:s=3D"=
uuid:BDC6E3F0-6DA3-11d1-A2A3-00AA00C14882" xmlns:rs=3D"urn:schemas-microsof=
t-com:rowset" xmlns:z=3D"#RowsetSchema" xmlns:b=3D"urn:schemas-microsoft-co=
m:office:publisher" xmlns:ss=3D"urn:schemas-microsoft-com:office:spreadshee=
t" xmlns:c=3D"urn:schemas-microsoft-com:office:component:spreadsheet" xmlns=
:odc=3D"urn:schemas-microsoft-com:office:odc" xmlns:oa=3D"urn:schemas-micro=
soft-com:office:activation" xmlns:html=3D"http://www.w3.org/TR/REC-html40" =
xmlns:q=3D"http://schemas.xmlsoap.org/soap/envelope/" xmlns:rtc=3D"http://m=
icrosoft.com/officenet/conferencing" xmlns:D=3D"DAV:" xmlns:Repl=3D"http://=
schemas.microsoft.com/repl/" xmlns:mt=3D"http://schemas.microsoft.com/share=
point/soap/meetings/" xmlns:x2=3D"http://schemas.microsoft.com/office/excel=
/2003/xml" xmlns:ppda=3D"http://www.passport.com/NameSpace.xsd" xmlns:ois=
=3D"http://schemas.microsoft.com/sharepoint/soap/ois/" xmlns:dir=3D"http://=
schemas.microsoft.com/sharepoint/soap/directory/" xmlns:ds=3D"http://www.w3=
.org/2000/09/xmldsig#" xmlns:dsp=3D"http://schemas.microsoft.com/sharepoint=
/dsp" xmlns:udc=3D"http://schemas.microsoft.com/data/udc" xmlns:xsd=3D"http=
://www.w3.org/2001/XMLSchema" xmlns:sub=3D"http://schemas.microsoft.com/sha=
repoint/soap/2002/1/alerts/" xmlns:ec=3D"http://www.w3.org/2001/04/xmlenc#"=
 xmlns:sp=3D"http://schemas.microsoft.com/sharepoint/" xmlns:sps=3D"http://=
schemas.microsoft.com/sharepoint/soap/" xmlns:xsi=3D"http://www.w3.org/2001=
/XMLSchema-instance" xmlns:udcs=3D"http://schemas.microsoft.com/data/udc/so=
ap" xmlns:udcxf=3D"http://schemas.microsoft.com/data/udc/xmlfile" xmlns:udc=
p2p=3D"http://schemas.microsoft.com/data/udc/parttopart" xmlns:wf=3D"http:/=
/schemas.microsoft.com/sharepoint/soap/workflow/" xmlns:dsss=3D"http://sche=
mas.microsoft.com/office/2006/digsig-setup" xmlns:dssi=3D"http://schemas.mi=
crosoft.com/office/2006/digsig" xmlns:mdssi=3D"http://schemas.openxmlformat=
s.org/package/2006/digital-signature" xmlns:mver=3D"http://schemas.openxmlf=
ormats.org/markup-compatibility/2006" xmlns:m=3D"http://schemas.microsoft.c=
om/office/2004/12/omml" xmlns:mrels=3D"http://schemas.openxmlformats.org/pa=
ckage/2006/relationships" xmlns:spwp=3D"http://microsoft.com/sharepoint/web=
partpages" xmlns:ex12t=3D"http://schemas.microsoft.com/exchange/services/20=
06/types" xmlns:ex12m=3D"http://schemas.microsoft.com/exchange/services/200=
6/messages" xmlns:pptsl=3D"http://schemas.microsoft.com/sharepoint/soap/Sli=
deLibrary/" xmlns:spsl=3D"http://microsoft.com/webservices/SharePointPortal=
Server/PublishedLinksService" xmlns:Z=3D"urn:schemas-microsoft-com:" xmlns:=
st=3D"&#1;" xmlns=3D"http://www.w3.org/TR/REC-html40"><head><meta http-equi=
v=3DContent-Type content=3D"text/html; charset=3Dus-ascii"><meta name=3DGen=
erator content=3D"Microsoft Word 12 (filtered medium)"><style><!--
/* Font Definitions */
@font-face
	{font-family:"Cambria Math";
	panose-1:2 4 5 3 5 4 6 3 2 4;}
@font-face
	{font-family:Calibri;
	panose-1:2 15 5 2 2 2 4 3 2 4;}
@font-face
	{font-family:Tahoma;
	panose-1:2 11 6 4 3 5 4 4 2 4;}
/* Style Definitions */
p.MsoNormal, li.MsoNormal, div.MsoNormal
	{margin:0in;
	margin-bottom:.0001pt;
	font-size:11.0pt;
	font-family:"Calibri","sans-serif";}
a:link, span.MsoHyperlink
	{mso-style-priority:99;
	color:blue;
	text-decoration:underline;}
a:visited, span.MsoHyperlinkFollowed
	{mso-style-priority:99;
	color:purple;
	text-decoration:underline;}
p.MsoListParagraph, li.MsoListParagraph, div.MsoListParagraph
	{mso-style-priority:34;
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	margin-bottom:.0001pt;
	font-size:11.0pt;
	font-family:"Calibri","sans-serif";}
span.EmailStyle18
	{mso-style-type:personal;
	font-family:"Calibri","sans-serif";
	color:windowtext;}
span.EmailStyle19
	{mso-style-type:personal;
	font-family:"Calibri","sans-serif";
	color:#1F497D;}
span.EmailStyle20
	{mso-style-type:personal;
	font-family:"Calibri","sans-serif";
	color:#1F497D;}
span.EmailStyle21
	{mso-style-type:personal;
	font-family:"Calibri","sans-serif";
	color:#1F497D;}
span.EmailStyle22
	{mso-style-type:personal;
	font-family:"Calibri","sans-serif";
	color:#1F497D;}
span.EmailStyle23
	{mso-style-type:personal;
	font-family:"Calibri","sans-serif";
	color:#1F497D;}
span.EmailStyle24
	{mso-style-type:personal-reply;
	font-family:"Calibri","sans-serif";
	color:#1F497D;}
.MsoChpDefault
	{mso-style-type:export-only;
	font-size:10.0pt;}
@page WordSection1
	{size:8.5in 11.0in;
	margin:1.0in 1.0in 1.0in 1.0in;}
div.WordSection1
	{page:WordSection1;}
/* List Definitions */
@list l0
	{mso-list-id:4938225;
	mso-list-type:hybrid;
	mso-list-template-ids:-227900608 -1111431534 67698713 67698715 67698703 67=
698713 67698715 67698703 67698713 67698715;}
@list l0:level1
	{mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-.25in;
	color:#1F497D;}
@list l0:level2
	{mso-level-tab-stop:1.0in;
	mso-level-number-position:left;
	text-indent:-.25in;}
@list l0:level3
	{mso-level-tab-stop:1.5in;
	mso-level-number-position:left;
	text-indent:-.25in;}
@list l0:level4
	{mso-level-tab-stop:2.0in;
	mso-level-number-position:left;
	text-indent:-.25in;}
@list l0:level5
	{mso-level-tab-stop:2.5in;
	mso-level-number-position:left;
	text-indent:-.25in;}
@list l0:level6
	{mso-level-tab-stop:3.0in;
	mso-level-number-position:left;
	text-indent:-.25in;}
@list l0:level7
	{mso-level-tab-stop:3.5in;
	mso-level-number-position:left;
	text-indent:-.25in;}
@list l0:level8
	{mso-level-tab-stop:4.0in;
	mso-level-number-position:left;
	text-indent:-.25in;}
@list l0:level9
	{mso-level-tab-stop:4.5in;
	mso-level-number-position:left;
	text-indent:-.25in;}
ol
	{margin-bottom:0in;}
ul
	{margin-bottom:0in;}
--></style><!--[if gte mso 9]><xml>
<o:shapedefaults v:ext=3D"edit" spidmax=3D"1026" />
</xml><![endif]--><!--[if gte mso 9]><xml>
<o:shapelayout v:ext=3D"edit">
<o:idmap v:ext=3D"edit" data=3D"1" />
</o:shapelayout></xml><![endif]--></head><body lang=3DEN-US link=3Dblue vli=
nk=3Dpurple><div class=3DWordSection1><p class=3DMsoNormal><span style=3D'c=
olor:#1F497D'>Below is more information for the President, regarding domest=
ic AIDS, from Ira:<o:p></o:p></span></p><p class=3DMsoNormal><span style=3D=
'color:#1F497D'><o:p>&nbsp;</o:p></span></p><div><div style=3D'border:none;=
border-top:solid #B5C4DF 1.0pt;padding:3.0pt 0in 0in 0in'><p class=3DMsoNor=
mal><b><span style=3D'font-size:10.0pt;font-family:"Tahoma","sans-serif"'>F=
rom:</span></b><span style=3D'font-size:10.0pt;font-family:"Tahoma","sans-s=
erif"'> Ira Magaziner <br><b>Sent:</b> Thursday, December 08, 2011 11:46 AM=
<br><b>To:</b> Amitabh Desai<br><b>Subject:</b> FW: Pharma Agreements<o:p><=
/o:p></span></p></div></div><p class=3DMsoNormal><o:p>&nbsp;</o:p></p><p cl=
ass=3DMsoNormal><span style=3D'color:#1F497D'><o:p>&nbsp;</o:p></span></p><=
p class=3DMsoNormal><span style=3D'color:#1F497D'>Ami:</span><o:p></o:p></p=
><p class=3DMsoNormal><span style=3D'color:#1F497D'><o:p>&nbsp;</o:p></span=
></p><p class=3DMsoNormal><span style=3D'color:#1F497D'>Following is a list=
 of agreements we have forged with US and European pharmaceutical companies=
 and selected negotiations we are having with them that are in advanced sta=
ges.<o:p></o:p></span></p><p class=3DMsoNormal><o:p>&nbsp;</o:p></p><p clas=
s=3DMsoListParagraph style=3D'text-indent:-.25in;mso-list:l0 level1 lfo2'><=
![if !supportLists]><span style=3D'color:#1F497D'><span style=3D'mso-list:I=
gnore'>1.<span style=3D'font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nb=
sp;&nbsp;&nbsp; </span></span></span><![endif]><span style=3D'color:#1F497D=
'>An agreement with Pfizer on rifabutin to make it more widely available at=
 a low price.<o:p></o:p></span></p><p class=3DMsoNormal><span style=3D'colo=
r:#1F497D'><o:p>&nbsp;</o:p></span></p><p class=3DMsoListParagraph style=3D=
'text-indent:-.25in;mso-list:l0 level1 lfo2'><![if !supportLists]><span sty=
le=3D'color:#1F497D'><span style=3D'mso-list:Ignore'>2.<span style=3D'font:=
7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span=
></span><![endif]><span style=3D'color:#1F497D'>An agreement with J&amp;J o=
n rilpivirine which has led to significant revisions in their overall acces=
s and licensing approach which will dramatically lower prices.<o:p></o:p></=
span></p><p class=3DMsoNormal><span style=3D'color:#1F497D'><o:p>&nbsp;</o:=
p></span></p><p class=3DMsoListParagraph style=3D'text-indent:-.25in;mso-li=
st:l0 level1 lfo2'><![if !supportLists]><span style=3D'color:#1F497D'><span=
 style=3D'mso-list:Ignore'>3.<span style=3D'font:7.0pt "Times New Roman"'>&=
nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><![endif]><span st=
yle=3D'color:#1F497D'>An agreement with ViiV which is related to developing=
 a new pediatric product and is also leading to a revisions in their access=
 policy.&nbsp; <o:p></o:p></span></p><p class=3DMsoNormal><span style=3D'co=
lor:#1F497D'><o:p>&nbsp;</o:p></span></p><p class=3DMsoListParagraph style=
=3D'text-indent:-.25in;mso-list:l0 level1 lfo2'><![if !supportLists]><span =
style=3D'color:#1F497D'><span style=3D'mso-list:Ignore'>4.<span style=3D'fo=
nt:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></s=
pan></span><![endif]><span style=3D'color:#1F497D'>Several agreements for p=
rice reductions on LPV/r with Abbott in the context of the UNITAID program<=
o:p></o:p></span></p><p class=3DMsoNormal><span style=3D'color:#1F497D'><o:=
p>&nbsp;</o:p></span></p><p class=3DMsoListParagraph style=3D'text-indent:-=
.25in;mso-list:l0 level1 lfo2'><![if !supportLists]><span style=3D'color:#1=
F497D'><span style=3D'mso-list:Ignore'>5.<span style=3D'font:7.0pt "Times N=
ew Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><![end=
if]><span style=3D'color:#1F497D'>An &nbsp;agreement with BMS on ATV/r lice=
nsing <o:p></o:p></span></p><p class=3DMsoNormal><span style=3D'color:#1F49=
7D'><o:p>&nbsp;</o:p></span></p><p class=3DMsoListParagraph style=3D'text-i=
ndent:-.25in;mso-list:l0 level1 lfo2'><![if !supportLists]><span style=3D'c=
olor:#1F497D'><span style=3D'mso-list:Ignore'>6.<span style=3D'font:7.0pt "=
Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span=
><![endif]><span style=3D'color:#1F497D'>An agreement with Merck to lower p=
rices on a tiered basis for raltagravir<o:p></o:p></span></p><p class=3DMso=
Normal><span style=3D'color:#1F497D'><o:p>&nbsp;</o:p></span></p><p class=
=3DMsoListParagraph style=3D'text-indent:-.25in;mso-list:l0 level1 lfo2'><!=
[if !supportLists]><span style=3D'color:#1F497D'><span style=3D'mso-list:Ig=
nore'>7.<span style=3D'font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbs=
p;&nbsp;&nbsp; </span></span></span><![endif]><span style=3D'color:#1F497D'=
>An agreement with Novartis on licensing ACT malaria drugs<o:p></o:p></span=
></p><p class=3DMsoListParagraph><span style=3D'color:#1F497D'><o:p>&nbsp;<=
/o:p></span></p><p class=3DMsoListParagraph style=3D'text-indent:-.25in;mso=
-list:l0 level1 lfo2'><![if !supportLists]><span style=3D'color:#1F497D'><s=
pan style=3D'mso-list:Ignore'>8.<span style=3D'font:7.0pt "Times New Roman"=
'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><![endif]><span=
 style=3D'color:#1F497D'>Agreements with Gilead that led to their liberal l=
icensing program<o:p></o:p></span></p><p class=3DMsoListParagraph><span sty=
le=3D'color:#1F497D'><o:p>&nbsp;</o:p></span></p><p class=3DMsoListParagrap=
h style=3D'text-indent:-.25in;mso-list:l0 level1 lfo2'><![if !supportLists]=
><span style=3D'color:#1F497D'><span style=3D'mso-list:Ignore'>9.<span styl=
e=3D'font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </s=
pan></span></span><![endif]><span style=3D'color:#1F497D'>An agreement with=
 GSK to drastically lower the price of rotavirus vaccine.<o:p></o:p></span>=
</p><p class=3DMsoNormal><span style=3D'color:#1F497D'><o:p>&nbsp;</o:p></s=
pan></p><p class=3DMsoNormal><span style=3D'color:#1F497D'>In addition, we =
are currently in discussions with Merck and GSK about HPV vaccine, with GSK=
, Sanofi and J&amp;J about polio vaccine and hexavalent vaccine formulation=
s and GSK about malaria vaccine.<o:p></o:p></span></p><p class=3DMsoNormal>=
<span style=3D'color:#1F497D'><o:p>&nbsp;</o:p></span></p><p class=3DMsoNor=
mal><span style=3D'color:#1F497D'>Thanks<o:p></o:p></span></p><p class=3DMs=
oNormal><span style=3D'color:#1F497D'><o:p>&nbsp;</o:p></span></p><p class=
=3DMsoNormal><span style=3D'color:#1F497D'>Ira<o:p></o:p></span></p><p clas=
s=3DMsoNormal><span style=3D'color:#1F497D'><o:p>&nbsp;</o:p></span></p><p =
class=3DMsoNormal><span style=3D'color:#1F497D'><o:p>&nbsp;</o:p></span></p=
><p class=3DMsoNormal><span style=3D'color:#1F497D'><o:p>&nbsp;</o:p></span=
></p><p class=3DMsoNormal><span style=3D'color:#1F497D'><o:p>&nbsp;</o:p></=
span></p><p class=3DMsoNormal><span style=3D'color:#1F497D'><o:p>&nbsp;</o:=
p></span></p><p class=3DMsoNormal><span style=3D'color:#1F497D'><o:p>&nbsp;=
</o:p></span></p><p class=3DMsoNormal><span style=3D'color:#1F497D'><o:p>&n=
bsp;</o:p></span></p><div><div style=3D'border:none;border-top:solid #B5C4D=
F 1.0pt;padding:3.0pt 0in 0in 0in'><p class=3DMsoNormal><b><span style=3D'f=
ont-size:10.0pt;font-family:"Tahoma","sans-serif"'>From:</span></b><span st=
yle=3D'font-size:10.0pt;font-family:"Tahoma","sans-serif"'> Kate Condliffe =
<br><b>Sent:</b> Thursday, December 08, 2011 11:02 AM<br><b>To:</b> Ira Mag=
aziner; David Ripin<br><b>Cc:</b> Alan Staple<br><b>Subject:</b> RE: <o:p><=
/o:p></span></p></div></div><p class=3DMsoNormal><o:p>&nbsp;</o:p></p><p cl=
ass=3DMsoNormal><span style=3D'color:#1F497D'>Copying Alan who will have th=
e most recent list.<o:p></o:p></span></p><p class=3DMsoNormal><span style=
=3D'color:#1F497D'><o:p>&nbsp;</o:p></span></p><div><div style=3D'border:no=
ne;border-top:solid #B5C4DF 1.0pt;padding:3.0pt 0in 0in 0in'><p class=3DMso=
Normal><b><span style=3D'font-size:10.0pt;font-family:"Tahoma","sans-serif"=
'>From:</span></b><span style=3D'font-size:10.0pt;font-family:"Tahoma","san=
s-serif"'> Ira Magaziner <br><b>Sent:</b> Thursday, December 08, 2011 10:56=
 AM<br><b>To:</b> David Ripin; Kate Condliffe<br><b>Subject:</b> <o:p></o:p=
></span></p></div></div><p class=3DMsoNormal><o:p>&nbsp;</o:p></p><p class=
=3DMsoNormal>I have been asked to supply a list of agreements we have done =
or are doing with Big Pharmaceutical companies (non generic). I know the va=
ccine ones. Could you please send me a list of others?<o:p></o:p></p><p cla=
ss=3DMsoNormal><o:p>&nbsp;</o:p></p><p class=3DMsoNormal>Thanks<o:p></o:p><=
/p><p class=3DMsoNormal><o:p>&nbsp;</o:p></p><p class=3DMsoNormal>Ira<o:p><=
/o:p></p></div></body></html>=

--_000_D00800C9D48A754DA64285EA077375750127C53AB1CLINTON07utop_--
